Table 2.
Ongoing clinical trials to evaluate TGF-β pathway antagonists.
| Target | Agent | Tumor type | Starting date | identifier |
|---|---|---|---|---|
| TβRI AR |
Galunisertib Enzalutamide |
Metastatic Castration-resistant Prostate Cancer | 2015-05-22 | NCT02452008 |
| α-TGF-β α- PD - 1 |
NIS793 PDR001 |
Breast Cancer Lung Cancer Hepatocellular Cancer Colorectal Cancer Pancreatic Cancer Renal Cancer |
2016-10-27 | NCT02947165 |
| TGF-βR1 ALK5 |
Vactosertib Pomalidomide |
Multiple Myeloma | 2017-05-08 | NCT03143985 |
| TGF-β PD-L1 |
M7824 | Pretreated MSI-H mCRC | 2018-02-19 | NCT03436563 |
| PD-L1 TGF-β |
M7825 | Breast Cancer | 2018-05-14 | NCT03524170 |
| PDL1 TGF-β |
M7824 Eribulin Mesylate |
TNBC | 2018-07-06 | NCT03579472 |
| PD-L1 TGF-β |
M7824 Topotecan Temozolomide |
SCLC | 2018-06-13 | NCT03554473 |
| TGF-β | Vactosertib imatinib |
Desmoid Tumor | 2019-01-14 | NCT03802084 |
| TGF-β PD-L1 |
Platinum-based regimen + M7824 | Metastatic NSCLC | 2019-02-15 | NCT03840915 |
| TGF-β PD-L1 |
M7824 With cCRT | NSCLC | 2019-02-15 | NCT03840902 |
| TGF-βR1 | Pembrolizumab vactosertib |
Colorectal Cancer Resectable Hepatic Metastases |
2019-02-18 | NCT03844750 |
| TGF-βR1 | Vactosertib | Myeloproliferative Neoplasm | 2019-09-25 | NCT04103645 |
| PD-L1/TGF-β | M7824 | Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma | 2020-01-07 | NCT04220775 |
| PD-L1 TGF-β |
M7824 | Cervical Cancer | 2020-01-29 | NCT04246489 |
| TGF-β PD-1 |
Gemcitabine nab-paclitaxel NIS793 Spartalizumab |
First-line Metastatic Pancreatic Ductal Adenocarcinoma | 2020-05-18 | NCT04390763 |
| PDL1 TGF-β |
M7824 | Thymoma Thymic Carcinoma |
2020-06-05 | NCT04417660 |
| PD-L1 TGF-β |
M7824 | Thymic Epithelial Tumor | 2020-06-05 | NCT04417660 |
| PD-L1 TGF-β |
M7824 | Recurrent Thymoma | 2020-06-05 | NCT04417660 |
| PD-L1 TGF-β |
M7824 | Thymic Cancer | 2020-06-05 | NCT04417660 |
| PD-L1 TGF-β |
PRGN-2009 M7824 |
Cervical cancers p16+ Oropharyngeal cancers Anal cancers Other locally advanced or metastatic solid tumors (e.g. lung, esophagus) that are known HPV+. |
2020-06-16 | NCT04432597 |
| TGF-βR1 ALK5 | Vactosertib 300 mg BID pembrolizumab 200 mg IV |
Non-Small-Cell Lung | 2020-08-17 | NCT04515979 |
| PD-L1 TGF-β |
M7824 NHS-IL12 Entinostat |
Cervical Oropharyngeal Anal Vulvar Vaginal |
2021-01-14 | NCT04708470 |
The underlined NCT Number represents the National Clinical Trial number, which is an identification that ClinicalTrials.gov assigns a study when it is registered. The NCT number is assigned when the study is registered.